2024
Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator
Mahal A, Yu J, Mahal R, Tien C, Adefres B, Damast S. Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator. Brachytherapy 2024, 23: s72-s73. DOI: 10.1016/j.brachy.2024.08.099.Peer-Reviewed Original ResearchVisual-analogue-scaleVaginal brachytherapyVaginal stretchingVaginal applicationEndometrial cancerAssociated with less painIr-192 seedsDose fall-offClinically significant responseProspective clinical trialPatient-centered evaluationVaginal introitusProspective trialsDose distributionSurface doseVaginal mucosaIr-192Less painNarrow introitusPaired t-testEC patientsConsenting patientsClinical trialsIntroitusPatientsThe Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy
Sherwani Z, Damast S, Fields E, Shah S, Beriwal S, Horne Z, Parks E, Kidd E, Leung E, Khoja L, Taunk N, Chino J, Huang C, Russo A, Dyer M, Albuquerque K, Hathout L. The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s32. DOI: 10.1016/j.ijrobp.2024.07.044.Peer-Reviewed Original ResearchRecurrence-free survivalExternal beam radiationMismatch repair statusOverall survivalAdjuvant radiotherapyVaginal brachytherapyAssociated with decreased RFSPromoter hypermethylationInferior recurrence-free survivalProportion of locoregional recurrenceTreated with adjuvant radiotherapyDepth of myometrial invasionLympho-vascular space invasionMulti-institutional cohort studyRetrospective multi-institutional cohort studyCervical stromal involvementSite of recurrenceKaplan Meier methodPost-surgical resectionCox proportional hazards modelsMulti-institutional studyDeficient mismatch repairProportional hazards modelImpact OSLocoregional recurrencePrognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis
Hathout L, Sherwani Z, Alegun J, Ohri N, Fields E, Shah S, Beriwal S, Horne Z, Kidd E, Leung E, Song J, Taunk N, Chino J, Huang C, Russo A, Dyer M, Li J, Albuquerque K, Damast S. Prognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2024, 119: 1158-1165. PMID: 38253292, DOI: 10.1016/j.ijrobp.2024.01.203.Peer-Reviewed Original ResearchRecurrence-free survivalEndometrioid endometrial adenocarcinomaMismatch repair statusAdjuvant radiation therapyOverall survivalRadiation therapyVaginal brachytherapyMismatch repair deficiencyAssociated with worse recurrence-free survivalMulti-institutional retrospective cohort studyTreated with adjuvant radiation therapyAssociated with recurrence-free survivalMultivariate analysisExternal beam radiation therapyRecurrence-free survival ratesMismatch repair deficiency statusBeam radiation therapyGrades 1 to 2Kaplan-Meier methodOutcomes of patientsMulti-institutional analysisRetrospective cohort studyCox proportional hazards modelsProportional hazards modelAdjuvant radiation
2021
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR status
2020
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaExternal beam RTVaginal brachytherapyOverall survivalHuman epidermal growth factor receptorModern treatment eraSentinel node samplingRegional nodal recurrenceKaplan-Meier estimatesLog-rank testCox proportional hazardsExternal beam radiotherapyEpidermal growth factor receptorERA treatmentGrowth factor receptorUSC patientsFree survivalNodal recurrenceTreatment eraMultimodality treatmentPatient characteristicsPerioperative periodRegional nodalSerous carcinomaNode sampling
2019
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy
Hochreiter A, Kelly JR, Young MR, Litkouhi B, Black JD, Stromberger C, Higgins S, Schwartz PE, Damast S. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy. International Journal Of Gynecological Cancer 2019, 30: 48. PMID: 31722964, DOI: 10.1136/ijgc-2019-000675.Peer-Reviewed Original ResearchConceptsDisease-free survivalLower uterine segment involvementPelvic recurrence-free survivalStage IB grade 2Uterine segment involvementLymph node dissectionRecurrence-free survivalEndometrial cancerRisk factorsVaginal brachytherapyOverall survivalGrade 2Endometrioid histologyNode dissectionPelvic recurrenceSegment involvementLymph nodesMyometrial invasionMultivariable Cox proportional hazards regressionEarly-stage endometrial cancerUnderwent lymph node dissectionCox proportional hazards regressionReduced disease-free survivalAdjuvant vaginal brachytherapySole adjuvant therapyOutcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical staging
Hochreiter A, Kelly J, Young M, Litkouhi B, Black J, Stromberger C, Higgins S, Schwartz P, Damast S. Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical staging. Gynecologic Oncology 2019, 154: 287. DOI: 10.1016/j.ygyno.2019.04.674.Peer-Reviewed Original Research
2018
Predictors of Pelvic Recurrence in Stage IB Grade 2-3 Endometrioid Endometrial Adenocarcinoma Treated with Post-Operative Vaginal Brachytherapy
Young M, Stahl J, Black J, Litkouhi B, Damast S. Predictors of Pelvic Recurrence in Stage IB Grade 2-3 Endometrioid Endometrial Adenocarcinoma Treated with Post-Operative Vaginal Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e656-e657. DOI: 10.1016/j.ijrobp.2018.07.1780.Peer-Reviewed Original Research
2017
Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
Qian JM, Stahl JM, Young MR, Ratner E, Damast S. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal Of Gynecologic Oncology 2017, 28: 0. PMID: 29027402, PMCID: PMC5641534, DOI: 10.3802/jgo.2017.28.e84.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBody Mass IndexBrachytherapyConstriction, PathologicDatabases, FactualEndometrial NeoplasmsFemaleGastrointestinal DiseasesGravidityHumansHysterectomyLymph Node ExcisionMiddle AgedNeoplasm StagingOvariectomyRadiation InjuriesRadiotherapy, AdjuvantSalpingectomyTreatment OutcomeVaginaVaginal DiseasesConceptsVaginal brachytherapyVaginal symptomsLate grade 3 toxicityEarly-stage endometrial cancerNormal body mass indexAdjuvant vaginal brachytherapyGrade 3 toxicityShorter vaginal lengthStage endometrial cancerEndometrial cancer patientsBody mass indexRate of recurrenceAcute gastrointestinalTreatment tolerabilityVaginal stenosisEndometrial cancerVaginal lengthMass indexRecurrence rateCancer patientsVaginal toxicityTreatment characteristicsHigh riskSide effectsPatients
2015
High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.Peer-Reviewed Original ResearchRecurrence-free survivalUterine serous carcinomaComprehensive surgical stagingOverall survivalSurgical stagingSerous carcinomaPara-aortic lymph node dissectionFIGO 2009 stage ICarboplatin-paclitaxel chemotherapyInstitutional chart reviewIsolated vaginal recurrencesSimultaneous lung metastasisLymph node dissectionPelvic control rateKaplan-Meier methodRate vaginal brachytherapyCases of recurrenceMedian followNode dissectionPeritoneal cytologyVaginal brachytherapyVaginal recurrenceTotal hysterectomyChart reviewBrachytherapy dose